<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Matrix metalloproteinases (MMPs) play an important role in the degradation of extracellular matrix components crucial for <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>, invasion and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>MMPs are controlled by natural inhibitors called tissue inhibitors of metalloproteinases (TIMPs) </plain></SENT>
<SENT sid="2" pm="."><plain>We and others have demonstrated that MMPs and TIMPs are especially important in the process of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invasion, progression and the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>It has been proposed that MMPs and TIMPs might play a part not only in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invasion and initiation of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> but also in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> from colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Several recent studies demonstrated that high preoperative serum or plasma MMP-2, MMP-9 and TIMP-1 antigen levels are strong predictive factors for poor prognosis in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and their determination might be useful for identification of patients with higher risk for <z:e sem="disease" ids="C0920420" disease_type="Neoplastic Process" abbrv="">cancer recurrence</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>MMP-9 and TIMP-1 have significant potential <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker impact in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Their diagnostic sensitivity is consistently higher than those of conventional biomarkers </plain></SENT>
<SENT sid="7" pm="."><plain>The pharmacological targeting of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> by the development of a new generation of selective inhibitors of MMPs, that is highly specific for certain MMPs, is a promising and challenging area for the future </plain></SENT>
</text></document>